 | | Vol. 24.32 – 25 September, 2023 |
| |
|
|
| Temperature-sensitive hydrogel conjugated with antibodies for the pro-inflammatory cytokine interleukin-6 and subcutaneously injected before the infusion of CAR-T cells substantially reduced the levels of IL-6 during cytokine release syndrome while maintaining the therapy’s antitumor efficacy.
[Nature Biomedical Engineering] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists investigated how CAR T cell expansion dynamics and serum proteomics affected neutrophil recovery phenotypes after CD19-directed CAR T cell therapy.
[Science Advances] |
|
|
|
| In this Phase I/II clinical trial, 65 pediatric and adult patients with refractory/relapsed T cell acute lymphoblastic leukemia and lymphoblastic lymphoma were enrolled.
[American Journal Of Hematology] |
|
|
|
| Scientists performed whole transcriptome analysis, reticulin fibrosis assessment, and CD3 T-cell infiltration on bone marrow core biopsies from pre- and post-CAR timepoints for 61 patients, as well as on a cohort of 54 primary B-acute lymphoblastic leukemia samples.
[American Journal Of Hematology] |
|
|
|
| Investigators explored whether targeting CD74 using a CAR-T cell would provide potent and durable anti-mantle cell lymphoma activity. They engineered a second generation anti-CD74 CAR with 4-1BB and CD3ζ signaling domains.
[Experimental Hematology & Oncology] |
|
|
|
| Researchers investigated the therapeutic application of CAR-macrophages in ovarian cancer. They constructed novel CAR structures, which consisted of humanized anti-HER2 or CD47 scFv, CD8 hinge region, and transmembrane domains, as well as the 4-1BB and CD3ζ intracellular domains.
[Journal Of Translational Medicine] |
|
|
|
| Investigators conducted a registry analysis including adult acute myeloid leukemia (AML) patients in remission who had received thiotepa, busulfan, and fludarabine or treosulfan-basedconditioning for haplo-hematopoietic stem cell transplant with posttransplant cyclophosphamide between 2010 and 2020.
[Hemasphere] |
|
|
|
| Scientists compared the effects of single versus double transplantation of Wharton’s jelly mesenchymal stromal cells on left ventricular ejection fraction post-acute myocardial infarction.
[Stem Cell Research & Therapy] |
|
|
|
| Investigators engineered CAR133-i502-NK92 cells and demonstrated that those cells displayed enhanced proliferation and specific anti-tumor activities in vitro and in a xenogeneic mouse model, and were well-tolerated.
[Cancer Biology & Medicine] |
|
|
|
|
| The authors summarize recent advances in mRNA-based CAR immunotherapies and highlight their opportunities and challenges for the development of a new generation of living drugs.
[Trends In Biotechnology] |
| |
|
|
| Base editing, which makes specific changes to a cell’s genome, is put to the test in CAR-T-cell treatments for leukemia. The first participant had been treated using immune cells with four base-edited genes, equipping the cells to better target and destroy tumors.
[Nature] |
|
|
|
|
| October 16 – 19, 2023
Hong Kong |
|
|
|
|
|
| | Novartis – Cambridge, Massachusetts, United States |
|
|
|
| | Technical University of Denmark – Copenhagen, Denmark |
|
|
|
| | City of Hope – Duarte, California United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Creative Biolabs – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
